Joint Venture (JV) combines CENTOGENE’s global leadership in multiomics with local insight of Lifera, a…
Joint Venture (JV) combines CENTOGENE’s global leadership in multiomics with local insight of Lifera, a…
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP),…
SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP),…
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated…
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated…
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features,…
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods…
USPTO and WIPO both publish two adrulipase patent applications for composition of matter and methods…
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with…
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with…
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for…
BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for…
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial…
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial…
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s…
AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer’s…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…
Complete elimination of viral load in 100% of patients at day 7 vs 6% in…